December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Arrowhead Pharma (NQ: ARWR )

82.07 USD +2.05 (+2.56%)
Official Closing Price Updated: 7:48 PM EST, Jan 22, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Arrowhead Pharma

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results
Arrowhead to release earnings and hold conference call on February 4 2021 
From Business Wire News Releases
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4) 
From Business Wire News Releases
NeuBase Therapeutics Announces Appointment of Curt Bradshaw, Ph.D. as Chief Scientific Officer
From GlobeNewswire News Releases
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
Arrowhead will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference and 20th Gordon L. Snider Critical Issues Workshop 
From Business Wire News Releases
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda
Arrowhead completes collaboration and license agreement with Takeda Pharmaceutical Company Limited 
From Business Wire News Releases
Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results
Arrowhead announced financial results for its fiscal year ended September 30, 2020 
From Business Wire News Releases
Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020
Arrowhead announced positive clinical data from multiple product candidates in its cardiometabolic pipeline at the American Heart Association 
From Business Wire News Releases
Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
Arrowhead announced positive interim clinical data at The AASLD Liver Meeting Digital Experience 
From Business Wire News Releases
Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
Arrowhead Pharmaceuticals will Participate in multiple Upcoming November 2020 Conferences 
From Business Wire News Releases
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
Arrowhead will host KOL webinars on two investigational RNAi based cardiometabolic candidates ARO-APOC3 and ARO-ANG3 
From Business Wire News Releases
Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results
Arrowhead Pharmaceuticals will webcast its fiscal 2020 year end earnings 
From Business Wire News Releases
Thinking about trading options or stock in Arrowhead Pharmaceuticals, Nio Inc, Raven Industries, Apple, or Carnival Corp?
InvestorsObserver issues critical PriceWatch Alerts for ARWR, NIO, RAVN, AAPL, and CCL. 
From PR Newswire
Thinking about trading options or stock in General Electric, Roku, CareDx Inc, Arrowhead Pharmaceuticals, or Eli Lilly?
InvestorsObserver issues critical PriceWatch Alerts for GE, ROKU, CDNA, ARWR, and LLY. 
From PR Newswire
Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Takeda and Arrowhead announced a collaboration and licensing agreement to develop ARO-AAT, a Ph. 2 investigational RNAi therapy to treat AATLD. 
From Business Wire News Releases
Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference
Arrowhead to participate in Chardan Genetic Medicines Conference 
From Business Wire News Releases
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead reports inducement grants 
From Business Wire News Releases
Thinking about trading options or stock in Arrowhead Pharmaceuticals, United Parcel Service, MGM Resorts, Moderna, or Microsoft?
InvestorsObserver issues critical PriceWatch Alerts for ARWR, UPS, MGM, MRNA, and MSFT. 
From PR Newswire
Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment
Arrowhead positive interim 24-week liver biopsy clinical trial results for ARO-AAT in alpha-1 antitrypsin deficiency improves Key Parameters 
From Business Wire News Releases
Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors
Arrowhead appoints veteran pharmaceutical industry executive Oye Olukotun, M.D., MPH, as an independent director of the company 
From Business Wire News Releases
Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences
Arrowhead Pharmaceuticals to present at multiple investor conferences in September 2020 
From Business Wire News Releases
Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020
Arrowhead Pharmaceuticals positive new Phase 1/2 clinical data on two RNAi-based cardiometabolic candidates ARO-APOC3 and ARO-ANG3 at ESC Congress 
From Business Wire News Releases
Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
Arrowhead and Janssen present Phase clinical data on hepatitis B treatment JNJ-3989 at EASL International Liver Congress 2020 
From Business Wire News Releases
Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences
Arrowhead Pharmaceuticals to present at August 2020 conferences 
From Business Wire News Releases
Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Arrowhead dosed the first patient in a clinical trial of RNAi based ARO-HIF2 for treatment of renal cell carcinoma 
From Business Wire News Releases
Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis
Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis 
From Business Wire News Releases
Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results
Arrowhead Pharmaceuticals reports fiscal Q3 2020 earnings results and hosts conference call 
From Business Wire News Releases
Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890
Amgen pays Arrowhead $20 million milestone for start of Phase 2 study of AMG 890 formerly ARO-LPA 
From Business Wire News Releases
Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
Arrowhead Pharmaceuticals and Marcus Mall MD host a webinar on ARO-ENaC for the treatment of cystic fibrosis 
From Business Wire News Releases
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Arrowhead reports inducement grants 
From Business Wire News Releases
Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
Arrowhead Pharma will host a KOL webinar on ARO-ENaC for treatment of cystic fibrosis 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.